VK Gadi, MD, PhD, of the University of Illinois Cancer Center, joins the show for a deep dive into antibody-drug conjugates (ADCs) in breast cancer, tracing the history and basic science that fueled their development and early interest in the field. Dr. Gadi breaks down where ADCs currently fit in breast cancer care, including key toxicities, evolving data presented at ESMO, and findings that may support FDA approval in early-stage and neoadjuvant HER2-positive disease. The conversation also explores advances in TROP-2–expressing and HER2-low disease, along with practical insights on incorporating and sequencing these agents in earlier lines of therapy.

Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/

Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA